Creative Planning boosted its position in Emergent Biosolutions Inc (NYSE:EBS) by 1.2% during the second quarter, Holdings Channel reports. The institutional investor owned 4,555 shares of the biopharmaceutical company’s stock after buying an additional 55 shares during the period. Creative Planning’s holdings in Emergent Biosolutions were worth $154,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Acadian Asset Management LLC increased its position in shares of Emergent Biosolutions by 1.4% in the first quarter. Acadian Asset Management LLC now owns 1,400,091 shares of the biopharmaceutical company’s stock worth $40,658,000 after buying an additional 18,739 shares in the last quarter. Bank of America Corp DE increased its position in shares of Emergent Biosolutions by 31.0% in the first quarter. Bank of America Corp DE now owns 234,902 shares of the biopharmaceutical company’s stock worth $6,821,000 after buying an additional 55,626 shares in the last quarter. Airain ltd purchased a new position in shares of Emergent Biosolutions during the first quarter worth about $461,000. Teachers Advisors LLC increased its position in shares of Emergent Biosolutions by 20.0% in the fourth quarter. Teachers Advisors LLC now owns 369,704 shares of the biopharmaceutical company’s stock worth $12,141,000 after buying an additional 61,658 shares in the last quarter. Finally, Rice Hall James & Associates LLC increased its position in shares of Emergent Biosolutions by 36.1% in the first quarter. Rice Hall James & Associates LLC now owns 531,006 shares of the biopharmaceutical company’s stock worth $15,420,000 after buying an additional 140,906 shares in the last quarter. Institutional investors own 85.48% of the company’s stock.

Shares of Emergent Biosolutions Inc (NYSE:EBS) traded up 0.38% during mid-day trading on Friday, hitting $34.27. 97,747 shares of the stock traded hands. Emergent Biosolutions Inc has a one year low of $24.47 and a one year high of $36.95. The stock has a 50-day moving average of $34.84 and a 200 day moving average of $31.47. The stock has a market cap of $1.41 billion, a PE ratio of 21.83 and a beta of 1.22.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by $0.13. Emergent Biosolutions had a return on equity of 3.01% and a net margin of 4.58%. The company had revenue of $100.77 million for the quarter, compared to analyst estimates of $111.57 million. During the same period in the previous year, the business posted ($0.05) EPS. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. Equities analysts predict that Emergent Biosolutions Inc will post $1.55 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/creative-planning-purchases-55-shares-of-emergent-biosolutions-inc-ebs/1475827.html.

EBS has been the subject of a number of recent research reports. Zacks Investment Research downgraded shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. BidaskClub upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. Emergent Biosolutions has an average rating of “Hold” and an average price target of $44.00.

In other news, Chairman Fuad El-Hibri sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 27th. The shares were sold at an average price of $36.50, for a total transaction of $912,500.00. Following the completion of the sale, the chairman now owns 1,630,216 shares of the company’s stock, valued at $59,502,884. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 16.50% of the stock is currently owned by company insiders.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.